BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72 Suppl 2:ii116-ii123. [PMID: 23253932 DOI: 10.1136/annrheumdis-2012-202371] [Cited by in Crossref: 196] [Cited by in F6Publishing: 180] [Article Influence: 21.8] [Reference Citation Analysis]
Number Citing Articles
1 Grieco FA, Moore F, Vigneron F, Santin I, Villate O, Marselli L, Rondas D, Korf H, Overbergh L, Dotta F, Marchetti P, Mathieu C, Eizirik DL. IL-17A increases the expression of proinflammatory chemokines in human pancreatic islets. Diabetologia 2014;57:502-11. [PMID: 24352375 DOI: 10.1007/s00125-013-3135-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
2 Croxford AL, Karbach S, Kurschus FC, Wörtge S, Nikolaev A, Yogev N, Klebow S, Schüler R, Reissig S, Piotrowski C, Brylla E, Bechmann I, Scheller J, Rose-john S, Thomas Wunderlich F, Münzel T, von Stebut E, Waisman A. IL-6 Regulates Neutrophil Microabscess Formation in IL-17A-Driven Psoriasiform Lesions. Journal of Investigative Dermatology 2014;134:728-35. [DOI: 10.1038/jid.2013.404] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 8.9] [Reference Citation Analysis]
3 Park SH, Chen WC, Esmaeil N, Lucas B, Marsh LM, Reibman J, Grunig G. Interleukin 13- and interleukin 17A-induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollution. Pulm Circ 2014;4:654-68. [PMID: 25610601 DOI: 10.1086/678511] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
4 Fleige H, Ravens S, Moschovakis GL, Bölter J, Willenzon S, Sutter G, Häussler S, Kalinke U, Prinz I, Förster R. IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J Exp Med 2014;211:643-51. [PMID: 24663215 DOI: 10.1084/jem.20131737] [Cited by in Crossref: 112] [Cited by in F6Publishing: 97] [Article Influence: 16.0] [Reference Citation Analysis]
5 Cada DJ, Baker DE, Panther SG, PharmD KI. Secukinumab. Hosp Pharm 2015;50:714-27. [PMID: 26823621 DOI: 10.1310/hpj5008-714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Torphy TJ, Allen J, Cantin AM, Konstan MW, Accurso FJ, Joseloff E, Ratjen FA, Chmiel JF; Antiinflammatory Therapy Working Group. Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. Ann Am Thorac Soc 2015;12:1398-406. [PMID: 26146892 DOI: 10.1513/AnnalsATS.201506-361OT] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
7 Talamonti M, Galluzzo M, van den Reek J, de Jong E, Lambert J, Malagoli P, Bianchi L, Costanzo A. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol 2017;177:489-96. [DOI: 10.1111/bjd.15387] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 8.5] [Reference Citation Analysis]
8 Lee S, Jeong J, Kim K, Kim D. Lactobacillus sakei OK67 ameliorates collagen-induced arthritis in mice by inhibiting NF-κB activation and restoring Th17/Treg cell balance. Journal of Functional Foods 2015;18:501-11. [DOI: 10.1016/j.jff.2015.08.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
9 Chen W, Kong Y, Li W, Zhou Y, Wu M, Chen T, Wu Y, Qiao H, Qiu Z, Qiu J. Generation and characterization of a humanized anti-IL-17A rabbit monoclonal antibody. Protein Expr Purif 2021;187:105950. [PMID: 34363980 DOI: 10.1016/j.pep.2021.105950] [Reference Citation Analysis]
10 Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 2019;21:111. [PMID: 31046809 DOI: 10.1186/s13075-019-1882-2] [Cited by in Crossref: 98] [Cited by in F6Publishing: 69] [Article Influence: 49.0] [Reference Citation Analysis]
11 Venkatesha SH, Dudics S, Acharya B, Moudgil KD. Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci 2014;16:887-906. [PMID: 25561237 DOI: 10.3390/ijms16010887] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
12 Pleyer U, Stübiger N. New pharmacotherapy options for noninfectious posterior uveitis. Expert Opinion on Biological Therapy 2014;14:1783-99. [DOI: 10.1517/14712598.2014.956074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 McElvaney OJ, Wade P, Murphy M, Reeves EP, McElvaney NG. Targeting airway inflammation in cystic fibrosis. Expert Rev Respir Med 2019;13:1041-55. [PMID: 31530195 DOI: 10.1080/17476348.2019.1666715] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
14 Liu Z, Liu H, Xu P, Yin Q, Wang Y, Opoku YK, Yang J, Song L, Sun X, Zhang T, Yu D, Wang X, Ren G, Li D. Ameliorative effects of a fusion protein dual targeting interleukin 17A and tumor necrosis factor α on imiquimod-induced psoriasis in mice. Biomedicine & Pharmacotherapy 2018;108:1425-34. [DOI: 10.1016/j.biopha.2018.09.178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Gong J, Noel S, Pluznick JL, Hamad ARA, Rabb H. Gut Microbiota-Kidney Cross-Talk in Acute Kidney Injury. Semin Nephrol. 2019;39:107-116. [PMID: 30606403 DOI: 10.1016/j.semnephrol.2018.10.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
16 Ratay ML, Bellotti E, Gottardi R, Little SR. Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation. Adv Healthc Mater 2017;6. [PMID: 29034584 DOI: 10.1002/adhm.201700733] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
17 Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11:415-429. [PMID: 25907700 DOI: 10.1038/nrrheum.2015.53] [Cited by in Crossref: 190] [Cited by in F6Publishing: 172] [Article Influence: 31.7] [Reference Citation Analysis]
18 Yin H, Fang X, Ma J, Chen M, Yang Y, Guo S, Chen Z, Su Z, Feng L, Ye P, Wu F, Yin J. Idiopathic Choroidal Neovascularization: Intraocular Inflammatory Cytokines and the Effect of Intravitreal Ranibizumab Treatment. Sci Rep 2016;6:31880. [PMID: 27558944 DOI: 10.1038/srep31880] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
19 Zhang Y, Shao Z, Zhang X, Jia X, Xia Y, Zhang Y, Xin N, Guo M, Chen J, Zheng S, Wang Y, Fu L, Dong R, Xiao C, Geng D, Liu Y. TIPE2 Play a Negative Role in TLR4-Mediated Autoimmune T Helper 17 Cell Responses in Patients with Myasthenia Gravis. J Neuroimmune Pharmacol 2015;10:635-44. [DOI: 10.1007/s11481-015-9638-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
20 Postal M, Sinicato NA, Appenzeller S, Niewold TB. Drugs in early clinical development for Systemic Lupus Erythematosus. Expert Opin Investig Drugs 2016;25:573-83. [PMID: 26950689 DOI: 10.1517/13543784.2016.1162291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
21 Ho AW, Garg AV, Monin L, Simpson-Abelson MR, Kinner L, Gaffen SL. The anaphase-promoting complex protein 5 (AnapC5) associates with A20 and inhibits IL-17-mediated signal transduction. PLoS One 2013;8:e70168. [PMID: 23922952 DOI: 10.1371/journal.pone.0070168] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
22 Luckey D, Behrens M, Smart M, Luthra H, David CS, Taneja V. DRB1*0402 may influence arthritis by promoting naive CD4+ T-cell differentiation in to regulatory T cells. Eur J Immunol 2014;44:3429-38. [PMID: 25103892 DOI: 10.1002/eji.201344424] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
23 Mulay SR, Linkermann A, Anders HJ. Necroinflammation in Kidney Disease. J Am Soc Nephrol 2016;27:27-39. [PMID: 26334031 DOI: 10.1681/ASN.2015040405] [Cited by in Crossref: 115] [Cited by in F6Publishing: 54] [Article Influence: 19.2] [Reference Citation Analysis]
24 Li Q, Liu W, Gao S, Mao Y, Xin Y. Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist. BMC Immunol 2021;22:11. [PMID: 33509093 DOI: 10.1186/s12865-021-00401-3] [Reference Citation Analysis]
25 Wood PR, Caplan L. Drug-Induced Gastrointestinal and Hepatic Disease Associated with Biologics and Nonbiologic Disease-Modifying Antirheumatic Drugs. Rheumatic Disease Clinics of North America 2018;44:29-43. [DOI: 10.1016/j.rdc.2017.09.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
26 Shen F, Verma AH, Volk A, Jones B, Coleman BM, Loza MJ, Malaviya R, Moore B, Weinstock D, Elloso MM, Gaffen SL, Ort T. Combined Blockade of TNF-α and IL-17A Alleviates Progression of Collagen-Induced Arthritis without Causing Serious Infections in Mice. J Immunol 2019;202:2017-26. [PMID: 30745461 DOI: 10.4049/jimmunol.1801436] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
27 Gupta PK, Wagner SR, Wu Q, Shilling RA. IL-17A Blockade Attenuates Obliterative Bronchiolitis and IFN-γ Cellular Immune Response in Lung Allografts. Am J Respir Cell Mol Biol 2017;56:708-15. [PMID: 28118023 DOI: 10.1165/rcmb.2016-0154OC] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
28 Yıldırım FE, Hapa FA. Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey. Journal of Dermatological Treatment. [DOI: 10.1080/09546634.2020.1839009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Pinto-Almeida T, Torres T. Biologic therapy for psoriasis - still searching for the best target. An Bras Dermatol 2014;89:365-7. [PMID: 24770527 DOI: 10.1590/abd1806-4841.20142898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 So A, Inman RD. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis. Best Pract Res Clin Rheumatol 2018;32:453-71. [PMID: 31171315 DOI: 10.1016/j.berh.2018.12.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
31 Mize MT, Sun XL, Simecka JW. Interleukin-17A Exacerbates Disease Severity in BALB/c Mice Susceptible to Lung Infection with Mycoplasma pulmonis. Infect Immun 2018;86:e00292-18. [PMID: 29986888 DOI: 10.1128/IAI.00292-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
32 Yan JW, Wang YJ, Peng WJ, Tao JH, Wan YN, Li BZ, Mei B, Chen B, Yao H, Yang GJ, Li XP, Ye DQ, Wang J. Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases. Expert Opin Ther Targets 2014;18:29-41. [PMID: 24147601 DOI: 10.1517/14728222.2013.843669] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
33 Wei JC, Baeten D, Sieper J, Deodhar A, Bhosekar V, Martin R, Porter B. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies. Int J Rheum Dis 2017;20:589-96. [DOI: 10.1111/1756-185x.13094] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
34 Willing A, Jäger J, Reinhardt S, Kursawe N, Friese MA. Production of IL-17 by MAIT Cells Is Increased in Multiple Sclerosis and Is Associated with IL-7 Receptor Expression. J Immunol 2018;200:974-82. [PMID: 29298833 DOI: 10.4049/jimmunol.1701213] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
35 Blair HA, Dhillon S. Secukinumab: A Review in Ankylosing Spondylitis. Drugs 2016;76:1023-30. [DOI: 10.1007/s40265-016-0598-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
36 Conti HR, Huppler AR, Whibley N, Gaffen SL. Animal models for candidiasis. Curr Protoc Immunol 2014;105:19.6.1-19.6.17. [PMID: 24700323 DOI: 10.1002/0471142735.im1906s105] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
37 Fauber BP, Magnuson S. Modulators of the Nuclear Receptor Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc). J Med Chem 2014;57:5871-92. [DOI: 10.1021/jm401901d] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 17.3] [Reference Citation Analysis]
38 Galluzzo M, D'Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther 2020;20:173-82. [PMID: 31880166 DOI: 10.1080/14712598.2020.1708897] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
39 Alinejad V, Dolati S, Motallebnezhad M, Yousefi M. The role of IL17B-IL17RB signaling pathway in breast cancer. Biomedicine & Pharmacotherapy 2017;88:795-803. [DOI: 10.1016/j.biopha.2017.01.120] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
40 Herrath J, Chemin K, Albrecht I, Catrina AI, Malmström V. Surface expression of CD39 identifies an enriched Treg-cell subset in the rheumatic joint, which does not suppress IL-17A secretion. Eur J Immunol 2014;44:2979-89. [PMID: 24990235 DOI: 10.1002/eji.201344140] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
41 Lee J, Lee S, Kang C, Jhun JY, Kim JH, Cho M, Park S, Kim H, Kwok S. Interleukin-17 Enhances Germinal Center Formation and Immunoglobulin G1 Production in Mice. J Rheum Dis 2017;24:271. [DOI: 10.4078/jrd.2017.24.5.271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Hassan M, Karkhur S, Bae JH, Halim MS, Ormaechea MS, Onghanseng N, Nguyen NV, Afridi R, Sepah YJ, Do DV, Nguyen QD. New therapies in development for the management of non-infectious uveitis: A review. Clin Exp Ophthalmol 2019;47:396-417. [PMID: 30938012 DOI: 10.1111/ceo.13511] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
43 Basdeo SA, Cluxton D, Sulaimani J, Moran B, Canavan M, Orr C, Veale DJ, Fearon U, Fletcher JM. Ex-Th17 (Nonclassical Th1) Cells Are Functionally Distinct from Classical Th1 and Th17 Cells and Are Not Constrained by Regulatory T Cells. J Immunol 2017;198:2249-59. [PMID: 28167631 DOI: 10.4049/jimmunol.1600737] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 14.0] [Reference Citation Analysis]
44 Tamassia N, Bianchetto-Aguilera F, Arruda-Silva F, Gardiman E, Gasperini S, Calzetti F, Cassatella MA. Cytokine production by human neutrophils: Revisiting the "dark side of the moon". Eur J Clin Invest 2018;48 Suppl 2:e12952. [PMID: 29772063 DOI: 10.1111/eci.12952] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 17.7] [Reference Citation Analysis]
45 Kavanaugh A, McInnes IB, Mease PJ, Hall S, Chinoy H, Kivitz AJ, Wang Z, Mpofu S. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. J Rheumatol 2016;43:1713-7. [PMID: 27307536 DOI: 10.3899/jrheum.160275] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 10.6] [Reference Citation Analysis]
46 Lin X, Tawch S, Wong HT, Roy S, Gaudino S, Castillo P, Elsegeiny W, Wakabayashi N, Oury TD, Pociask D, Chen K, McLinskey N, Melville P, Syritsyna O, Coyle P, Good M, Awasthi A, Kolls JK, Kumar P. Nrf2 through Aryl Hydrocarbon Receptor Regulates IL-22 Response in CD4+ T Cells. J Immunol 2021;206:1540-8. [PMID: 33648937 DOI: 10.4049/jimmunol.1900656] [Reference Citation Analysis]
47 Melnik BC, John SM, Chen W, Plewig G. T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities. Br J Dermatol 2018;179:260-72. [PMID: 29573406 DOI: 10.1111/bjd.16561] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
48 Xiao S, Yosef N, Yang J, Wang Y, Zhou L, Zhu C, Wu C, Baloglu E, Schmidt D, Ramesh R, Lobera M, Sundrud MS, Tsai PY, Xiang Z, Wang J, Xu Y, Lin X, Kretschmer K, Rahl PB, Young RA, Zhong Z, Hafler DA, Regev A, Ghosh S, Marson A, Kuchroo VK. Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity 2014;40:477-89. [PMID: 24745332 DOI: 10.1016/j.immuni.2014.04.004] [Cited by in Crossref: 192] [Cited by in F6Publishing: 168] [Article Influence: 27.4] [Reference Citation Analysis]
49 Zhang D, Li B, Guo R, Wu J, Yang C, Jiang X, Zhang C, Yan H, Zhao Q, Wang Z, Wang Q, Huang R, Zhang Z, Hu X, Gao L. RAB5C, SYNJ1, and RNF19B promote male ankylosing spondylitis by regulating immune cell infiltration. Ann Transl Med 2021;9:1011. [PMID: 34277811 DOI: 10.21037/atm-21-2721] [Reference Citation Analysis]
50 Purvis HA, Anderson AE, Young DA, Isaacs JD, Hilkens CM. A negative feedback loop mediated by STAT3 limits human Th17 responses. J Immunol. 2014;193:1142-1150. [PMID: 24973454 DOI: 10.4049/jimmunol.1302467] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
51 Wu C, Goodall JC, Busch R, Gaston JS. Relationship of CD146 expression to secretion of interleukin (IL)-17, IL-22 and interferon-γ by CD4(+) T cells in patients with inflammatory arthritis. Clin Exp Immunol 2015;179:378-91. [PMID: 25113810 DOI: 10.1111/cei.12434] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
52 Paivandy A, Pejler G. Novel Strategies to Target Mast Cells in Disease. J Innate Immun 2021;13:131-47. [PMID: 33582673 DOI: 10.1159/000513582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
53 Wei M, Duan D. Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials. Drug Des Devel Ther 2016;10:2771-7. [PMID: 27672309 DOI: 10.2147/DDDT.S91374] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
54 Whibley N, Tritto E, Traggiai E, Kolbinger F, Moulin P, Brees D, Coleman BM, Mamo AJ, Garg AV, Jaycox JR, Siebenlist U, Kammüller M, Gaffen SL. Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis. J Leukoc Biol 2016;99:1153-64. [PMID: 26729813 DOI: 10.1189/jlb.4A0915-428R] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 7.6] [Reference Citation Analysis]
55 van Niel MB, Fauber BP, Cartwright M, Gaines S, Killen JC, René O, Ward SI, de Leon Boenig G, Deng Y, Eidenschenk C, Everett C, Gancia E, Ganguli A, Gobbi A, Hawkins J, Johnson AR, Kiefer JR, La H, Lockey P, Norman M, Ouyang W, Qin A, Wakes N, Waszkowycz B, Wong H. A reversed sulfonamide series of selective RORc inverse agonists. Bioorg Med Chem Lett 2014;24:5769-76. [PMID: 25453817 DOI: 10.1016/j.bmcl.2014.10.037] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
56 Harkins P, Conway R. Giant cell arteritis: what is new in the preclinical and early clinical development pipeline? Expert Opin Investig Drugs 2021;:1-12. [PMID: 34106030 DOI: 10.1080/13543784.2021.1940949] [Reference Citation Analysis]
57 Garzorz N, Papanagiotou V, Atenhan A, Andres C, Eyerich S, Eyerich K, Ring J, Brockow K. Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)-syndrome: a new entity within the spectrum of autoinflammatory syndromes? J Eur Acad Dermatol Venereol. 2014;Jul 28; Epub ahead of print. [PMID: 25070077 DOI: 10.1111/jdv.12631] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
58 Olivieri I, D'angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol 2014;10:531-42. [DOI: 10.1038/nrrheum.2014.106] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
59 Vassallo R, Luckey D, Behrens M, Madden B, Luthra H, David C, Taneja V. Cellular and humoral immunity in arthritis are profoundly influenced by the interaction between cigarette smoke effects and host HLA-DR and DQ genes. Clin Immunol 2014;152:25-35. [PMID: 24631425 DOI: 10.1016/j.clim.2014.02.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
60 Wang C, Yosef N, Gaublomme J, Wu C, Lee Y, Clish CB, Kaminski J, Xiao S, Meyer Zu Horste G, Pawlak M, Kishi Y, Joller N, Karwacz K, Zhu C, Ordovas-Montanes M, Madi A, Wortman I, Miyazaki T, Sobel RA, Park H, Regev A, Kuchroo VK. CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell Pathogenicity. Cell 2015;163:1413-27. [PMID: 26607793 DOI: 10.1016/j.cell.2015.10.068] [Cited by in Crossref: 189] [Cited by in F6Publishing: 164] [Article Influence: 31.5] [Reference Citation Analysis]
61 Simpson-Abelson MR, Hernandez-Mir G, Childs EE, Cruz JA, Poholek AC, Chattopadhyay A, Gaffen SL, McGeachy MJ. CCAAT/Enhancer-binding protein β promotes pathogenesis of EAE. Cytokine 2017;92:24-32. [PMID: 28088614 DOI: 10.1016/j.cyto.2017.01.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
62 Rada B. Interactions between Neutrophils and Pseudomonas aeruginosa in Cystic Fibrosis. Pathogens 2017;6:E10. [PMID: 28282951 DOI: 10.3390/pathogens6010010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
63 Gege C, Cummings MD, Albers M, Kinzel O, Kleymann G, Schlüter T, Steeneck C, Nelen MI, Milligan C, Spurlino J, Xue X, Leonard K, Edwards JP, Fourie A, Goldberg SD, Hoffmann T. Identification and biological evaluation of thiazole-based inverse agonists of RORγt. Bioorganic & Medicinal Chemistry Letters 2018;28:1446-55. [DOI: 10.1016/j.bmcl.2018.03.093] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
64 Iman M, Rezaei R, Azimzadeh Jamalkandi S, Shariati P, Kheradmand F, Salimian J. Th17/Treg immunoregulation and implications in treatment of sulfur mustard gas-induced lung diseases. Expert Rev Clin Immunol 2017;13:1173-88. [PMID: 28994328 DOI: 10.1080/1744666X.2017.1389646] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
65 Garg AV, Amatya N, Chen K, Cruz JA, Grover P, Whibley N, Conti HR, Hernandez Mir G, Sirakova T, Childs EC, Smithgall TE, Biswas PS, Kolls JK, McGeachy MJ, Kolattukudy PE, Gaffen SL. MCPIP1 Endoribonuclease Activity Negatively Regulates Interleukin-17-Mediated Signaling and Inflammation. Immunity 2015;43:475-87. [PMID: 26320658 DOI: 10.1016/j.immuni.2015.07.021] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 13.2] [Reference Citation Analysis]
66 Yu H, Zeng R, Lin Y, Li X, Tasneem S, Yang Z, Qiu Y, Li B, Wang Y, Cai X, Wang W. Kadsura heteroclita stem suppresses the onset and progression of adjuvant-induced arthritis in rats. Phytomedicine 2019;58:152876. [DOI: 10.1016/j.phymed.2019.152876] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
67 Akiho H, Tokita Y, Nakamura K, Satoh K, Nishiyama M, Tsuchiya N, Tsuchiya K, Ohbuchi K, Iwakura Y, Ihara E, Takayanagi R, Yamamoto M. Involvement of interleukin-17A-induced hypercontractility of intestinal smooth muscle cells in persistent gut motor dysfunction. PLoS One 2014;9:e92960. [PMID: 24796324 DOI: 10.1371/journal.pone.0092960] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
68 Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Current Opinion in Rheumatology 2015;27:127-33. [DOI: 10.1097/bor.0000000000000147] [Cited by in Crossref: 110] [Cited by in F6Publishing: 46] [Article Influence: 18.3] [Reference Citation Analysis]
69 Karri SK, Sheela A. Potential route of Th17/Treg cell dynamics in targeting type 1 diabetes and rheumatoid arthritis: an autoimmune disorder perspective. Br J Biomed Sci 2017;74:8-15. [PMID: 28074676 DOI: 10.1080/09674845.2016.1264704] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
70 Fu SH, Lin MH, Yeh LT, Wang YL, Chien MW, Lin SH, Chang DM, Sytwu HK. Targeting tumour necrosis factor receptor 1 assembly reverses Th17-mediated colitis through boosting a Th2 response. Gut. 2015;64:765-775. [PMID: 25011937 DOI: 10.1136/gutjnl-2013-306585] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
71 Lin H, Song P, Zhao Y, Xue LJ, Liu Y, Chu CQ. Targeting Th17 Cells with Small Molecules and Small Interference RNA. Mediators Inflamm 2015;2015:290657. [PMID: 26792955 DOI: 10.1155/2015/290657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
72 Selmi C, Generali E, Massarotti M, Bianchi G, Sciré CA. New treatments for inflammatory rheumatic disease. Immunol Res 2014;60:277-88. [PMID: 25381481 DOI: 10.1007/s12026-014-8565-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
73 Szczepanik A, Iasella CJ, McDyer JF, Ensor CR. Cytokine-targeted therapy for the management of solid organ transplant recipients. Hum Immunol 2019;80:184-90. [PMID: 30562564 DOI: 10.1016/j.humimm.2018.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Yang Y, Yang Y, Yang J, Xie R, Ren Y, Fan H. Regulatory effect of nicotine on collagen-induced arthritis and on the induction and function of in vitro-cultured Th17 cells. Modern Rheumatology 2013;24:781-7. [DOI: 10.3109/14397595.2013.862352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
75 Gaspari AA, Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther 2015;28:179-93. [PMID: 26201310 DOI: 10.1111/dth.12251] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 7.6] [Reference Citation Analysis]
76 Gunzer M. Traps and hyper inflammation - new ways that neutrophils promote or hinder survival. Br J Haematol 2014;164:189-99. [PMID: 24138538 DOI: 10.1111/bjh.12608] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
77 Cheng WC, Saleh F, Abuaisha Karim B, Hughes FJ, Taams LS. Comparative analysis of immune cell subsets in peripheral blood from patients with periodontal disease and healthy controls. Clin Exp Immunol 2018;194:380-90. [PMID: 30120837 DOI: 10.1111/cei.13205] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
78 Li DD, Bechara R, Ramani K, Jawale CV, Li Y, Kolls JK, Gaffen SL, Biswas PS. RTEC-intrinsic IL-17-driven inflammatory circuit amplifies antibody-induced glomerulonephritis and is constrained by Regnase-1. JCI Insight 2021;6:147505. [PMID: 34236049 DOI: 10.1172/jci.insight.147505] [Reference Citation Analysis]
79 Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf 2016;15:1413-20. [PMID: 27545070 DOI: 10.1080/14740338.2016.1221923] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 11.4] [Reference Citation Analysis]
80 Fabre JAS, Giustinniani J, Garbar C, Merrouche Y, Antonicelli F, Bensussan A. The Interleukin-17 Family of Cytokines in Breast Cancer. Int J Mol Sci 2018;19:E3880. [PMID: 30518157 DOI: 10.3390/ijms19123880] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
81 Tamassia N, Arruda-Silva F, Calzetti F, Lonardi S, Gasperini S, Gardiman E, Bianchetto-Aguilera F, Gatta LB, Girolomoni G, Mantovani A, Vermi W, Cassatella MA. A Reappraisal on the Potential Ability of Human Neutrophils to Express and Produce IL-17 Family Members In Vitro: Failure to Reproducibly Detect It. Front Immunol 2018;9:795. [PMID: 29719541 DOI: 10.3389/fimmu.2018.00795] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
82 Fiocco U, Accordi B, Martini V, Oliviero F, Facco M, Cabrelle A, Piva L, Molena B, Caso F, Costa L, Scanu A, Pagnin E, Atteno M, Scarpa R, Basso G, Semenzato G, Punzi L, Doria A, Dayer J. JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 2014;58:61-9. [DOI: 10.1007/s12026-013-8481-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
83 Picchianti-Diamanti A, Rosado MM, D'Amelio R. Infectious Agents and Inflammation: The Role of Microbiota in Autoimmune Arthritis. Front Microbiol 2017;8:2696. [PMID: 29387048 DOI: 10.3389/fmicb.2017.02696] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
84 Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585-600. [PMID: 25145755 DOI: 10.1038/nri3707] [Cited by in Crossref: 829] [Cited by in F6Publishing: 733] [Article Influence: 118.4] [Reference Citation Analysis]
85 Lückel C, Picard F, Raifer H, Campos Carrascosa L, Guralnik A, Zhang Y, Klein M, Bittner S, Steffen F, Moos S, Marini F, Gloury R, Kurschus FC, Chao YY, Bertrams W, Sexl V, Schmeck B, Bonetti L, Grusdat M, Lohoff M, Zielinski CE, Zipp F, Kallies A, Brenner D, Berger M, Bopp T, Tackenberg B, Huber M. IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis. Nat Commun 2019;10:5722. [PMID: 31844089 DOI: 10.1038/s41467-019-13731-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 16.5] [Reference Citation Analysis]
86 Johansen C, Mose M, Ommen P, Bertelsen T, Vinter H, Hailfinger S, Lorscheid S, Schulze-Osthoff K, Iversen L. IκBζ is a key driver in the development of psoriasis. Proc Natl Acad Sci U S A 2015;112:E5825-33. [PMID: 26460049 DOI: 10.1073/pnas.1509971112] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 11.3] [Reference Citation Analysis]
87 Kolbinger F, Loesche C, Valentin M, Jiang X, Cheng Y, Jarvis P, Peters T, Calonder C, Bruin G, Polus F, Aigner B, Lee DM, Bodenlenz M, Sinner F, Pieber TR, Patel DD. β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis. Journal of Allergy and Clinical Immunology 2017;139:923-932.e8. [DOI: 10.1016/j.jaci.2016.06.038] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 19.5] [Reference Citation Analysis]
88 Boniface K. Role of Th17 cells in the pathogenesis of rheumatoid arthritis. WJR 2013;3:25. [DOI: 10.5499/wjr.v3.i3.25] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 Poggi A, Benelli R, Venè R, Costa D, Ferrari N, Tosetti F, Zocchi MR. Human Gut-Associated Natural Killer Cells in Health and Disease. Front Immunol 2019;10:961. [PMID: 31130953 DOI: 10.3389/fimmu.2019.00961] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 19.5] [Reference Citation Analysis]
90 Conti HR, Whibley N, Coleman BM, Garg AV, Jaycox JR, Gaffen SL. Signaling through IL-17C/IL-17RE is dispensable for immunity to systemic, oral and cutaneous candidiasis. PLoS One 2015;10:e0122807. [PMID: 25849644 DOI: 10.1371/journal.pone.0122807] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
91 Barry RJ, Nguyen QD, Lee RW, Murray PI, Denniston AK. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol 2014;8:1891-911. [PMID: 25284976 DOI: 10.2147/OPTH.S47778] [Cited by in Crossref: 4] [Cited by in F6Publishing: 20] [Article Influence: 0.6] [Reference Citation Analysis]
92 Cao Y, Zhang W, Wu J, Zhang H, Zhou H. Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment. J Ophthalmol 2017;2017:7298026. [PMID: 28785483 DOI: 10.1155/2017/7298026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
93 Verdier J, Ruemmele FM. Molecular mechanisms and cell targets of Th17 cells in the gastrointestinal tract: an innate sense of adaptivity. Int Rev Immunol 2013;32:475-92. [PMID: 24069950 DOI: 10.3109/08830185.2013.829471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
94 Pușcaș AD, Cătană A, Pușcaș C, Roman II, Vornicescu C, Șomlea M, Orăsan RI. Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment. Exp Ther Med 2019;18:875-80. [PMID: 31384317 DOI: 10.3892/etm.2019.7624] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Truchetet ME, Mossalayi MD, Boniface K. IL-17 in the rheumatologist's line of sight. Biomed Res Int 2013;2013:295132. [PMID: 23984335 DOI: 10.1155/2013/295132] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
96 van Baarsen LG, Lebre MC, van der Coelen D, Aarrass S, Tang MW, Ramwadhdoebe TH, Gerlag DM, Tak PP. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther 2014;16:426. [PMID: 25146432 DOI: 10.1186/s13075-014-0426-z] [Cited by in Crossref: 96] [Cited by in F6Publishing: 80] [Article Influence: 13.7] [Reference Citation Analysis]
97 Koch Hansen L, Sevelsted-Møller L, Rabjerg M, Larsen D, Hansen TP, Klinge L, Wulff H, Knudsen T, Kjeldsen J, Köhler R. Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. J Crohns Colitis 2014;8:1378-91. [PMID: 24793818 DOI: 10.1016/j.crohns.2014.04.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
98 Keijsers RRMC, Joosten I, van Erp PEJ, Koenen HJPM, van de Kerkhof PCM. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp Dermatol 2014;23:799-803. [DOI: 10.1111/exd.12487] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 10.3] [Reference Citation Analysis]
99 Mease P, McInnes IB. Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatol Ther 2016;3:5-29. [PMID: 27747518 DOI: 10.1007/s40744-016-0031-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 7.4] [Reference Citation Analysis]
100 Reich K, Warren R, Coates L, Di Comite G. Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol 2020;34:1161-73. [DOI: 10.1111/jdv.16124] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
101 Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet 2021;397:475-86. [PMID: 33549192 DOI: 10.1016/S0140-6736(21)00126-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 17.0] [Reference Citation Analysis]
102 Lee JS, Cua DJ. The emerging landscape of RORγt biology. Immunity 2014;40:451-2. [PMID: 24745326 DOI: 10.1016/j.immuni.2014.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
103 Ferreira MC, Whibley N, Mamo AJ, Siebenlist U, Chan YR, Gaffen SL. Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis. Infect Immun 2014;82:1030-5. [PMID: 24343647 DOI: 10.1128/IAI.01389-13] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
104 Alunno A, Manetti M, Caterbi S, Ibba-Manneschi L, Bistoni O, Bartoloni E, Valentini V, Terenzi R, Gerli R. Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. Mediators Inflamm 2015;2015:751793. [PMID: 25918479 DOI: 10.1155/2015/751793] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 8.8] [Reference Citation Analysis]
105 Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125:2228-2233. [PMID: 25893595 DOI: 10.1172/jci78088] [Cited by in Crossref: 174] [Cited by in F6Publishing: 89] [Article Influence: 29.0] [Reference Citation Analysis]
106 Moudgil KD. Interplay among cytokines and T cell subsets in the progression and control of immune-mediated diseases. Cytokine 2015;74:1-4. [PMID: 26026376 DOI: 10.1016/j.cyto.2015.05.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
107 Montepaone M, Lubrano E, Carboni A, Spadaro A. Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis. Open Access Rheumatol 2014;6:7-13. [PMID: 27790030 DOI: 10.2147/OARRR.S56048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. Arch Immunol Ther Exp (Warsz) 2015;63:435-49. [PMID: 26062902 DOI: 10.1007/s00005-015-0344-z] [Cited by in Crossref: 116] [Cited by in F6Publishing: 93] [Article Influence: 19.3] [Reference Citation Analysis]
109 Navarro-Millán I, Curtis JR. Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis. Curr Opin Rheumatol. 2013;25:384-390. [PMID: 23511719 DOI: 10.1097/bor.0b013e32835fc62e] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
110 Mangan PR, Su LJ, Jenny V, Tatum AL, Picarillo C, Skala S, Ditto N, Lin Z, Yang X, Cotter PZ, Shuster DJ, Song Y, Borowski V, Thomas RL, Heimrich EM, Devaux B, Das Gupta R, Carvajal I, McIntyre KW, Xie J, Zhao Q, Struthers M, Salter-Cid LM. Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of Autoimmunity. J Pharmacol Exp Ther 2015;354:152-65. [PMID: 26015463 DOI: 10.1124/jpet.115.224246] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
111 Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis 2018;77:175-87. [PMID: 28765121 DOI: 10.1136/annrheumdis-2017-211555] [Cited by in Crossref: 159] [Cited by in F6Publishing: 126] [Article Influence: 39.8] [Reference Citation Analysis]
112 Shirley M, Scott LJ. Secukinumab: A Review in Psoriatic Arthritis. Drugs 2016;76:1135-45. [DOI: 10.1007/s40265-016-0602-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
113 Zafiriou E, Daponte AI, Siokas V, Tsigalou C, Dardiotis E, Bogdanos DP. Depression and Obesity in Patients With Psoriasis and Psoriatic Arthritis: Is IL-17-Mediated Immune Dysregulation the Connecting Link? Front Immunol 2021;12:699848. [PMID: 34367160 DOI: 10.3389/fimmu.2021.699848] [Reference Citation Analysis]
114 Ochi H. Mechanism of multiple sclerosis based on the clinical trial results of molecular targeted therapy. Clin Exp Neuroimmunol 2014;5:6-15. [DOI: 10.1111/cen3.12159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Bertelsen T, Ljungberg C, Boye Kjellerup R, Iversen L, Johansen C. IL-17F regulates psoriasis-associated genes through IκBζ. Exp Dermatol 2017;26:234-41. [PMID: 27576147 DOI: 10.1111/exd.13182] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
116 Harvima IT, Levi-schaffer F, Draber P, Friedman S, Polakovicova I, Gibbs BF, Blank U, Nilsson G, Maurer M. Molecular targets on mast cells and basophils for novel therapies. Journal of Allergy and Clinical Immunology 2014;134:530-44. [DOI: 10.1016/j.jaci.2014.03.007] [Cited by in Crossref: 94] [Cited by in F6Publishing: 78] [Article Influence: 13.4] [Reference Citation Analysis]
117 Wang R, Yang L, Zhang C, Wang R, Zhang Z, He Q, Chen X, Zhang B, Qin Z, Wang L, Zhang Y. Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer. Oncoimmunology 2018;7:e1461303. [PMID: 30377557 DOI: 10.1080/2162402X.2018.1461303] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
118 Góis M, Messias A, Carvalho D, Carvalho F, Sousa H, Sousa J, Nolasco F. MPO-ANCA-associated necrotizing glomerulonephritis in rheumatoid arthritis; a case report and review of literature. J Nephropathol 2017;6:58-62. [PMID: 28491854 DOI: 10.15171/jnp.2017.10] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
119 Kaur R, Rawat AK, Kumar S, Aadil W, Akhtar T, Narang T, Chopra D. Association of genetic polymorphism of interleukin-17A & interleukin-17F with susceptibility of psoriasis. Indian J Med Res 2018;148:422-6. [PMID: 30666004 DOI: 10.4103/ijmr.IJMR_1859_16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
120 An İ, Aksoy M, Ayhan E, Ozturk M. The effect of secukinumab treatment on inflammatory parameters in patients with psoriasis: A multicentre restrospective study. Int J Clin Pract 2021;75:e14114. [PMID: 33626203 DOI: 10.1111/ijcp.14114] [Reference Citation Analysis]
121 Cheng W, Hughes FJ, Taams LS. The presence, function and regulation of IL-17 and Th17 cells in periodontitis. J Clin Periodontol 2014;41:541-9. [DOI: 10.1111/jcpe.12238] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 11.3] [Reference Citation Analysis]
122 Huppler AR, Conti HR, Hernández-Santos N, Darville T, Biswas PS, Gaffen SL. Role of neutrophils in IL-17-dependent immunity to mucosal candidiasis. J Immunol 2014;192:1745-52. [PMID: 24442441 DOI: 10.4049/jimmunol.1302265] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 11.6] [Reference Citation Analysis]
123 Braun J. New targets in psoriatic arthritis. Rheumatology (Oxford) 2016;55:ii30-7. [PMID: 27856658 DOI: 10.1093/rheumatology/kew343] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
124 Shaw AT, Maeda Y, Gravallese EM. IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis. Arthritis Res Ther 2016;18:104. [PMID: 27165410 DOI: 10.1186/s13075-016-0998-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 9.4] [Reference Citation Analysis]
125 Palazzi C, D’angelo S, Gilio M, Leccese P, Padula A, Olivieri I. Pharmacological therapy of spondyloarthritis. Expert Opinion on Pharmacotherapy 2015;16:1495-504. [DOI: 10.1517/14656566.2015.1052744] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
126 Evans HG, Roostalu U, Walter GJ, Gullick NJ, Frederiksen KS, Roberts CA, Sumner J, Baeten DL, Gerwien JG, Cope AP. TNF-α blockade induces IL-10 expression in human CD4+ T cells. Nat Commun. 2014;5:3199. [PMID: 24492460 DOI: 10.1038/ncomms4199] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 11.3] [Reference Citation Analysis]
127 Silvagni E, Bortoluzzi A, Ciancio G, Govoni M. Biological and synthetic target DMARDs in psoriatic arthritis. Pharmacol Res 2019;149:104473. [PMID: 31585178 DOI: 10.1016/j.phrs.2019.104473] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
128 Pacheco-Tena C, González-Chávez SA. The danger model approach to the pathogenesis of the rheumatic diseases. J Immunol Res 2015;2015:506089. [PMID: 25973436 DOI: 10.1155/2015/506089] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
129 Curtin F, Hartung HP. Novel therapeutic options for multiple sclerosis. Expert Rev Clin Pharmacol 2014;7:91-104. [PMID: 24325127 DOI: 10.1586/17512433.2014.865517] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
130 Spadaro A, Lubrano E. Beyond anti-TNF-α agents in psoriatic arthritis. Expert Review of Clinical Immunology 2014;9:507-9. [DOI: 10.1586/eci.13.32] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
131 Astry B, Venkatesha SH, Moudgil KD. Involvement of the IL-23/IL-17 axis and the Th17/Treg balance in the pathogenesis and control of autoimmune arthritis. Cytokine 2015;74:54-61. [PMID: 25595306 DOI: 10.1016/j.cyto.2014.11.020] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
132 Fauber BP, de Leon Boenig G, Burton B, Eidenschenk C, Everett C, Gobbi A, Hymowitz SG, Johnson AR, Liimatta M, Lockey P, Norman M, Ouyang W, René O, Wong H. Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc. Bioorganic & Medicinal Chemistry Letters 2013;23:6604-9. [DOI: 10.1016/j.bmcl.2013.10.054] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
133 Striz I, Brabcova E, Kolesar L, Sekerkova A. Cytokine networking of innate immunity cells: a potential target of therapy. Clinical Science 2014;126:593-612. [DOI: 10.1042/cs20130497] [Cited by in Crossref: 133] [Cited by in F6Publishing: 51] [Article Influence: 19.0] [Reference Citation Analysis]
134 Blauvelt A, Lebwohl MG, Bissonnette R. IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies. J Invest Dermatol 2015;135:1946-53. [PMID: 25972190 DOI: 10.1038/jid.2015.144] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
135 Rai MF, Pan H, Yan H, Sandell LJ, Pham CTN, Wickline SA. Applications of RNA interference in the treatment of arthritis. Transl Res 2019;214:1-16. [PMID: 31351032 DOI: 10.1016/j.trsl.2019.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
136 Wang K, Kim MK, Di Caro G, Wong J, Shalapour S, Wan J, Zhang W, Zhong Z, Sanchez-Lopez E, Wu LW, Taniguchi K, Feng Y, Fearon E, Grivennikov SI, Karin M. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 2014;41:1052-63. [PMID: 25526314 DOI: 10.1016/j.immuni.2014.11.009] [Cited by in Crossref: 187] [Cited by in F6Publishing: 163] [Article Influence: 26.7] [Reference Citation Analysis]
137 Adami S, Cavani A, Rossi F, Girolomoni G. The Role of Interleukin-17A in Psoriatic Disease. BioDrugs 2014;28:487-97. [DOI: 10.1007/s40259-014-0098-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
138 Han L, Yang J, Wang X, Li D, Lv L, Li B. Th17 cells in autoimmune diseases. Front Med. 2015;9:10-19. [PMID: 25652649 DOI: 10.1007/s11684-015-0388-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
139 Chen X, Oppenheim JJ. Th17 cells and Tregs: unlikely allies. J Leukoc Biol 2014;95:723-31. [PMID: 24563509 DOI: 10.1189/jlb.1213633] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
140 Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother. 2018;101:287-292. [PMID: 29499402 DOI: 10.1016/j.biopha.2018.02.103] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 19.7] [Reference Citation Analysis]
141 Cockx M, Gouwy M, Van Damme J, Struyf S. Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases. Cell Mol Immunol 2018;15:312-23. [PMID: 29176750 DOI: 10.1038/cmi.2017.118] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
142 Prieto-Pérez R, Almoguera B, Cabaleiro T, Hakonarson H, Abad-Santos F. Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease. Int J Mol Sci 2016;17:225. [PMID: 26861312 DOI: 10.3390/ijms17020225] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
143 Gao W, Wu Y, Tian Y, Ni B. Yin–Yang Regulation of RORγt Protein Complex in Th17 Differentiation. International Reviews of Immunology 2015;34:295-304. [DOI: 10.3109/08830185.2014.969423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
144 Bishu S, Su EW, Wilkerson ER, Reckley KA, Jones DM, McGeachy MJ, Gaffen SL, Levesque MC. Rheumatoid arthritis patients exhibit impaired Candida albicans-specific Th17 responses. Arthritis Res Ther 2014;16:R50. [PMID: 24513269 DOI: 10.1186/ar4480] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
145 Fauny M, Moulin D, D'Amico F, Netter P, Petitpain N, Arnone D, Jouzeau JY, Loeuille D, Peyrin-Biroulet L. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis 2020;79:1132-8. [PMID: 32719044 DOI: 10.1136/annrheumdis-2020-217927] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 20.0] [Reference Citation Analysis]
146 Ma K, Du W, Xiao F, Han M, Huang E, Peng N, Tang Y, Deng C, Liu L, Chen Y, Li J, Yuan S, Huang Q, Hong X, Hu D, Cai X, Jiang Q, Liu D, Lu L. IL-17 sustains the plasma cell response via p38-mediated Bcl-xL RNA stability in lupus pathogenesis. Cell Mol Immunol 2021;18:1739-50. [PMID: 32917979 DOI: 10.1038/s41423-020-00540-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
147 Chimenti MS, Sunzini F, Fiorucci L, Botti E, Fonti GL, Conigliaro P, Triggianese P, Costa L, Caso F, Giunta A, Esposito M, Bianchi L, Santucci R, Perricone R. Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress. Front Immunol 2018;9:2363. [PMID: 30429845 DOI: 10.3389/fimmu.2018.02363] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
148 Kurdi AT, Bassil R, Olah M, Wu C, Xiao S, Taga M, Frangieh M, Buttrick T, Orent W, Bradshaw EM, Khoury SJ, Elyaman W. Tiam1/Rac1 complex controls Il17a transcription and autoimmunity. Nat Commun 2016;7:13048. [PMID: 27725632 DOI: 10.1038/ncomms13048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
149 Jimeno R, Leceta J, Garín M, Ortiz AM, Mellado M, Rodríguez-Frade JM, Martínez C, Pérez-García S, Gomariz RP, Juarranz Y. Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect. J Leukoc Biol 2015;98:257-69. [PMID: 25957307 DOI: 10.1189/jlb.3A0714-327R] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
150 Boonyarattanasoonthorn T, Elewa YHA, Tag-El-Din-Hassan HT, Morimatsu M, Agui T. Profiling of cellular immune responses to Mycoplasma pulmonis infection in C57BL/6 and DBA/2 mice. Infect Genet Evol 2019;73:55-65. [PMID: 31026602 DOI: 10.1016/j.meegid.2019.04.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
151 Hung AL, Lim M, Doshi TL. Targeting cytokines for treatment of neuropathic pain. Scand J Pain 2017;17:287-93. [PMID: 29229214 DOI: 10.1016/j.sjpain.2017.08.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 11.8] [Reference Citation Analysis]
152 Braun J, Baraliakos X, Kiltz U. Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy 2016;16:711-22. [DOI: 10.1517/14712598.2016.1167183] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
153 Hong J, Liu Z, Sun X, Xu J. Secukinumab in the Treatment of Noninfectious Uveitis. Ophthalmology 2013;120:e86. [DOI: 10.1016/j.ophtha.2013.08.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
154 Beringer A, Noack M, Miossec P. IL-17 in Chronic Inflammation: From Discovery to Targeting. Trends Mol Med. 2016;22:230-241. [PMID: 26837266 DOI: 10.1016/j.molmed.2016.01.001] [Cited by in Crossref: 216] [Cited by in F6Publishing: 193] [Article Influence: 43.2] [Reference Citation Analysis]
155 Wu X, Tian J, Wang S. Insight Into Non-Pathogenic Th17 Cells in Autoimmune Diseases. Front Immunol 2018;9:1112. [PMID: 29892286 DOI: 10.3389/fimmu.2018.01112] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 13.0] [Reference Citation Analysis]
156 Thorlacius L, Theut Riis P, Jemec G. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol 2018;179:182-5. [DOI: 10.1111/bjd.15769] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
157 Huang S, Zheng F, Lin H, Zhou X, Xu H, Zhang C, Dai W, Hocher B, Zhang X, Tang D, Dai Y. Quantitative proteomics analysis of lysine 2-hydroxyisobutyrylation in IgA nephropathy. Clin Proteomics 2021;18:7. [PMID: 33557746 DOI: 10.1186/s12014-021-09314-0] [Reference Citation Analysis]
158 Prieto-Pérez R, Cabaleiro T, Daudén E, Ochoa D, Roman M, Abad-Santos F. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis 2013;2013:613086. [PMID: 24069534 DOI: 10.1155/2013/613086] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
159 Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, Liu L, Bakoyannis G, Jiang D, Chu HW, Lobera M, Yang J, Wilkes DS, Du J, Gartlan K, Hill GR, MacDonald KP, Espada EL, Blanco P, Serody JS, Koreth J, Cutler CS, Antin JH, Soiffer RJ, Ritz J, Paczesny S, Blazar BR. An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight 2017;2:92111. [PMID: 28614794 DOI: 10.1172/jci.insight.92111] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
160 Braun J, Kiltz U, Heldmann F, Baraliakos X. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs 2015;20:1-14. [PMID: 25575936 DOI: 10.1517/14728214.2015.993378] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
161 Herjan T, Hong L, Bubenik J, Bulek K, Qian W, Liu C, Li X, Chen X, Yang H, Ouyang S, Zhou H, Zhao J, Vasu K, Cockman E, Aronica M, Asosingh K, Licatalosi DD, Qin J, Fox PL, Hamilton TA, Driscoll D, Li X. IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-17 inflammatory signaling. Nat Immunol 2018;19:354-65. [PMID: 29563620 DOI: 10.1038/s41590-018-0071-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
162 Selmi C. Unique topics and issues in rheumatology and clinical immunology. Clin Rev Allergy Immunol 2014;47:1-5. [PMID: 25086643 DOI: 10.1007/s12016-014-8441-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
163 Pineda MA, Al-Riyami L, Harnett W, Harnett MM. Lessons from helminth infections: ES-62 highlights new interventional approaches in rheumatoid arthritis. Clin Exp Immunol 2014;177:13-23. [PMID: 24666108 DOI: 10.1111/cei.12252] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
164 Fukayama M, Yoshizaki A, Fukasawa T, Ebata S, Kuzumi A, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S. Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis. J Dermatol 2020;47:1287-92. [PMID: 32686186 DOI: 10.1111/1346-8138.15508] [Reference Citation Analysis]
165 Kim SJ, Jang YW, Hyung KE, Lee DK, Hyun KH, Park SY, Park ES, Hwang KW. Therapeutic Effects of Methanol Extract from Euphorbia kansui Radix on Imiquimod-Induced Psoriasis. J Immunol Res 2017;2017:7052560. [PMID: 28761880 DOI: 10.1155/2017/7052560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
166 Wootla B, Watzlawik JO, Stavropoulos N, Wittenberg NJ, Dasari H, Abdelrahim MA, Henley JR, Oh SH, Warrington AE, Rodriguez M. Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opin Biol Ther 2016;16:827-39. [PMID: 26914737 DOI: 10.1517/14712598.2016.1158809] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
167 Dos Passos GR, Sato DK, Becker J, Fujihara K. Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications. Mediators Inflamm. 2016;2016:5314541. [PMID: 26941483 DOI: 10.1155/2016/5314541] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 9.6] [Reference Citation Analysis]
168 Linghang Q, Yiyi X, Guosheng C, Kang X, Jiyuan T, Xiong L, Guangzhong W, Shuiqing L, Yanju L. Effects of Atractylodes Oil on Inflammatory Response and Serum Metabolites in Adjuvant Arthritis Rats. Biomed Pharmacother 2020;127:110130. [PMID: 32289576 DOI: 10.1016/j.biopha.2020.110130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
169 Eskandarpour M, Alexander R, Adamson P, Calder VL. Pharmacological Inhibition of Bromodomain Proteins Suppresses Retinal Inflammatory Disease and Downregulates Retinal Th17 Cells. J Immunol 2017;198:1093-103. [PMID: 28039300 DOI: 10.4049/jimmunol.1600735] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
170 Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H; ERASURE Study Japanese subgroup. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 2014;41:1039-46. [PMID: 25354738 DOI: 10.1111/1346-8138.12668] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 7.9] [Reference Citation Analysis]
171 Manivel VA, Sohrabian A, Wick MC, Mullazehi M, Håkansson LD, Rönnelid J. Anti-type II collagen immune complex-induced granulocyte reactivity is associated with joint erosions in RA patients with anti-collagen antibodies. Arthritis Res Ther 2015;17:8. [PMID: 25598326 DOI: 10.1186/s13075-015-0523-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
172 Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and signaling. Cytokine. 2013;64:477-485. [PMID: 24011563 DOI: 10.1016/j.cyto.2013.07.022] [Cited by in Crossref: 291] [Cited by in F6Publishing: 257] [Article Influence: 36.4] [Reference Citation Analysis]
173 Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014;10:612-27. [DOI: 10.1038/nrrheum.2014.123] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
174 Benezeder T, Wolf P. Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). Semin Immunopathol 2019;41:633-44. [PMID: 31673756 DOI: 10.1007/s00281-019-00766-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
175 Christensen AD, Haase C, Cook AD, Hamilton JA. K/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory Arthritis. Front Immunol 2016;7:213. [PMID: 27313578 DOI: 10.3389/fimmu.2016.00213] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
176 Bellone M, Brevi A, Huber S. Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer. Microbiol Mol Biol Rev 2020;84:e00064-19. [PMID: 32132244 DOI: 10.1128/MMBR.00064-19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
177 Sabag DA, Matanes L, Bejar J, Sheffer H, Barzilai A, Church MK, Toubi E, Maurer M, Vadasz Z. Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy 2020;50:799-804. [PMID: 32412136 DOI: 10.1111/cea.13616] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
178 Lønnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol 2014;7:251-9. [PMID: 25246805 DOI: 10.2147/CCID.S67534] [Cited by in Crossref: 52] [Cited by in F6Publishing: 24] [Article Influence: 7.4] [Reference Citation Analysis]
179 Kamali AN, Noorbakhsh SM, Hamedifar H, Jadidi-Niaragh F, Yazdani R, Bautista JM, Azizi G. A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders. Mol Immunol 2019;105:107-15. [PMID: 30502718 DOI: 10.1016/j.molimm.2018.11.015] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 12.0] [Reference Citation Analysis]
180 Garg AV, Gaffen SL. IL-17 signaling and A20: a balancing act. Cell Cycle 2013;12:3459-60. [PMID: 24107622 DOI: 10.4161/cc.26699] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]